1. Home
  2. TROO vs MYGN Comparison

TROO vs MYGN Comparison

Compare TROO & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TROOPS Inc.

TROO

TROOPS Inc.

HOLD

Current Price

$3.96

Market Cap

480.1M

Sector

Technology

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$5.08

Market Cap

547.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TROO
MYGN
Founded
2005
1991
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
480.1M
547.2M
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
TROO
MYGN
Price
$3.96
$5.08
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
$10.67
AVG Volume (30 Days)
584.6K
952.6K
Earning Date
10-17-2025
02-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,084,000.00
$825,300,000.00
Revenue This Year
N/A
$0.05
Revenue Next Year
N/A
$5.54
P/E Ratio
N/A
N/A
Revenue Growth
247.24
0.21
52 Week Low
$0.49
$3.76
52 Week High
$5.28
$15.47

Technical Indicators

Market Signals
Indicator
TROO
MYGN
Relative Strength Index (RSI) 54.46 26.71
Support Level $3.57 $5.03
Resistance Level $4.45 $5.70
Average True Range (ATR) 0.36 0.26
MACD -0.06 -0.04
Stochastic Oscillator 49.32 4.00

Price Performance

Historical Comparison
TROO
MYGN

About TROO TROOPS Inc.

TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Share on Social Networks: